Targeted therapeuticts and their role in the treatment of internal diseases
- I. interní klinika 1. lékařské fakulty UK a VFN a ÚHKT Praha, přednosta prof. MUDr. Marek Trněný, CSc.
Targeted therapy is a conceptual notion that should be used for such a treatment approach that has been developed based upon the known pathophysiology and/or biomarkers of a particular disease, mainly malignancies. Monoclonal antibodies and tyrosine-kinase inhibitors were among the first molecularly targeted agents. Monoclonal antibodies approach is based on targeting a biomarker expressed either on the surface of cancer cells or targeting different cytokines. Tyrosin-kinase inhibitors are directed at the druggable molecule involved in the cancer pathophysiology inhibiting aberrant tyrosin-kinase activity. Classification of targeted drugs and their use in the clinical practice is shortly reviewed.
Keywords: targeted therapy; monoclonal antibodies; tyrosin-kinase inhibitors; classification; clinical use
Received: January 3, 2013; Published: January 1, 2013 Show citation
References
- Airley R. Cancer chemotherapy. Willey-Blackwell, Oxford 2009.
- Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. Appleton and Lange, Norwalk, 1994.
- Klener P. Klinická onkologie.Praha: Galén-Karolinum 2002.
- Mladosievičová B et al. Molekulové mechanizmy patogenézy nádorov. Bratislava: SAP 2011, 123 s.
- Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008; 35: 439-448.
Go to original source...
Go to PubMed...
- Mayer J, Klamová H, Žáčková D et al. Imatinib v první linii léčby s nově diagnostikovanou chronickou myeloidní leukemií v chronické fázi. Transfuze Hematol Dnes 2008; 15: 150-158.
- Klener P, Klener jr. P. Nová protinádorová léčiva a léčebné strategie v onkologii. Praha: Grada Publishingh 2010.
- Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth fractor (VEGF) inhibition - a critical review. Anticancer agents Med Chem 2007; 7:223-245.
Go to original source...
Go to PubMed...
- Hartman JT, Haap M, Koop HG et al. Tyrosine kinase inhibitors - a review on pharmacology metabolism and side effects. Curr Drug Metab 2009; 10: 470-481.
Go to original source...
Go to PubMed...
- Wong MK, Lo AL, Lam B et al. Erlotinib as a salvage treatment after failure of first line gefitinib in non small cell lung cancer. Cancer Chemother Pharmacol 2009; 64: 656-663.
- Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
Go to original source...
Go to PubMed...
- Chan S. Targeting the mammalian target of rapamycin (m-TOR): a new approach to treating cancer. Br J Cancer 2004; 25: 1420-1424.
Go to original source...
Go to PubMed...
- Klener P, Klener jr. P. ABL1, SRC a další nereceptorové proteinkinázy jako nové cíle specifické protinádorové terapie. Klin Onkol 2010; 23: 203-209.
Go to PubMed...
- Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol 2005; 23: 1147-1157.
Go to original source...
Go to PubMed...
- Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Natur Rev 2010; 10: 317-327.
Go to original source...
Go to PubMed...
- Belada D. Monoklonální protilátky v léčbě lymfomů. Remedia 2008; 6: 416-423.
- Tazi L, Nafil H, Mahmal L. Monoclonal antibodies in hematological malignancies: past, present and future. J Cancer Res Ther 2012; 7: 309-407.
Go to original source...
- Castillo J, Winer E, Quinsberry O. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36: 755-768.
Go to original source...
Go to PubMed...
- Palácová M. Trastuzumab. Remedia 2009; 20: 4-13.
- Van Cutsem E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med 2009; 369: 1408-1417.
Go to original source...
Go to PubMed...
- Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumor activity. Cancer 2008; 8: 579-591.
Go to original source...
- Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823-830.
Go to original source...
Go to PubMed...
- Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nature rev 2010; 10: 301-316.
Go to original source...
Go to PubMed...
- Choy EHS, Kingsley GH, Panayi GS. Monoclonal antibody therapy in rheumatoid arthritis. Brit J Rhematol 1998; 37: 484-490.
Go to original source...
Go to PubMed...
- Yuvienco C, Schwartz S. Monoclonal antibodies in rheumatic diseases. Med Health/Rhode Island 2011; 94: 320-324.
- Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease. Gastroenteology 2006; 130: 323-333.
Go to original source...
Go to PubMed...
- Kelly RJ, Hill A, Arnold LM et al. Long-term treatment with eculimumab in paroxaysmal nocturnal hemoglobinuria. Blood 2011; 117: 6786-6792.
Go to original source...
Go to PubMed...
- Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-904.
Go to original source...
Go to PubMed...
- Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14: 154-169.
Go to original source...
Go to PubMed...
- Kontermann RF. Recombinant bispecific antibodies for cancer. Acta Pharmacol 2005; 26: 1-9.
Go to original source...
Go to PubMed...
- Goldenberg DM, Cardillo IM, Shi V et al. Bispecific anti CD20/22 antibodies inhibit B-cell lymphoma proliferation by unique mechanism of action. Blood 2008; 111: 2211-2219.
Go to original source...
Go to PubMed...
- Nelson AI, Reichert JM. Development trends for therapeutic antibody fragments. Nature Biotechnol 2009; 27: 331-337.
Go to original source...
Go to PubMed...